Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?

<table class="fixed-width table-group" id="tab10"><tr><td><table class="table"><colgroup><col style="width:9.88em"/><col style="width:5.93em"/><col style="width:6.32em"/><col style="width:11.43em"/></colgroup><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left">Therapeutic modality</td><td class="align_center">OS rate (%)</td><td class="align_center">CSS rate (%)</td><td class="align_center">Surgery-free survival rate</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">RP</td><td class="align_center">91,3</td><td class="align_center">95,6</td><td class="align_center">100,0</td></tr><tr><td class="align_left">NLT</td><td class="align_center">78,9</td><td class="align_center">84,2</td><td class="align_center">71,1</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>OS: overall survival; CSS: cancer-specific survival; RP: radical prostatectomy; NLT: no local treatment.<br/></div></td></tr></table>

<div>Overall survival and surgery-free survival rate by therapeutic modality, adapted from Heidenreich et al. [<a href="/journals/pc/2018/2654572/#B26" target="_blank">18</a>].</div>

Prostate Cancer

tab10

Table 10

Table 10: Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far? 